• Orthofix posted Q2 net sales of USD 210.9 million, up 4% from a year earlier.
• Net loss widened to USD 15.8 million, or USD 0.39 a share.
• Non-GAAP adjusted EBITDA edged down to USD 20.1 million, from USD 20.6 million.
• Cash, cash equivalents and restricted cash fell to USD 104.4 million, due to arbitration award and settlement payments.
• Raised 2026 net sales outlook to USD 845 million-USD 855 million; lifted non-GAAP adjusted EBITDA view to USD 95 million-USD 98 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Orthofix Medical Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260805908825) on August 05, 2026, and is solely responsible for the information contained therein.